Androgen blockage with radiotherapy boosts event-free prostate cancer survival

Four months of androgen blockade increased event-free survival at 5 years in patients with intermediate-risk prostate adenocarcinoma when treated with high-dose radiotherapy, a multicenter randomized phase III trial showed. Longer follow-up is required to demonstrate an impact on overall survival, Bernard M. Dubray, MD, PhD, of the Centre Henri Becquerel of the University of Rouen in France, reported in a poster presentation at the American Society of Clinical Oncology annual meeting.
Medpage Today